Refractory Indolent Non-Hodgkin Lymphoma
4 clinical trials · Condition
◉ Watch Refractory Indolent Non-Hodgkin Lymphoma
| Record | Firm | Date |
|---|---|---|
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia (NCT07166419) | Ohio State University Comprehensive Cancer Center | 2026-01-14 |
| Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma (NCT06386315) | Mayo Clinic | 2024-05-15 |
| Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (NCT04836832) | Narendranath Epperla | 2022-07-01 |
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (NCT05418088) | Sumithira Vasu | 2022-06-30 |
Track Refractory Indolent Non-Hodgkin Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.